Poor
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Several contraindication-related claims are partially supported, but multiple claims extend beyond or misstate label language (e.g., liver disease/persistent enzyme elevations, hypersensitivity, breastfeeding). Pregnancy discontinuation guidance is broadly consistent, but overall accuracy is poor due to unsupported/overbroad contraindications.
Category Scores
Accurate Statements
If a patient becomes pregnant while taking a statin, the usual approach is to stop the medication and consult the prescribing clinician.
Supported by Section 4.3 Pregnancy: “If the patient becomes pregnant while taking this drug, LIPITOR should be discontinued immediately and the patient apprised of the potential hazard to the fetus...” (consulting clinician is not explicitly stated, but discontinuation is supported).
If liver tests become abnormal after starting Lipitor therapy, clinicians typically reassess ongoing treatment and repeat labs rather than continuing automatically.
Supported directionally by Section 5.2 Liver Dysfunction: liver function tests performed prior to and at 12 weeks after initiation/titration; “Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of LIPITOR is recommended.”
Unsupported Statements
Lipitor (atorvastatin) is contraindicated in people with active liver disease.
Section 5.2 states active liver disease is a contraindication, but the excerpt cites “Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of LIPITOR [see Contraindications (4.1)].” The user claim is broadly consistent, but the provided contraindications excerpt (4.3 Pregnancy) does not explicitly include the active liver disease contraindication; label support is therefore incomplete from the excerpts provided.
Lipitor (atorvastatin) is contraindicated in people with unexplained persistent elevations of liver enzymes.
Section 5.2 supports that “Active liver disease or unexplained persistent transaminase elevations are contraindications,” but the provided Contraindications section excerpt shown is only Pregnancy (4.3). With only the provided excerpts, this is not fully anchored to the Contraindications section text.
Lipitor (atorvastatin) is contraindicated in people with hypersensitivity to atorvastatin or to any ingredient in the product.
No hypersensitivity contraindication is present in the provided excerpts (Sections 1, 2, 4 (only Pregnancy excerpt), 5, 6, 7, 8).
Lipitor (atorvastatin) is contraindicated during breastfeeding.
No breastfeeding contraindication or breastfeeding-specific warning excerpt is provided in the supplied label text.
Lipitor should not be used during breastfeeding.
No breastfeeding-specific guidance is provided in the supplied label excerpts.
Lipitor should not be used during pregnancy.
Pregnancy contraindication is supported (contraindicated in women who are or may become pregnant; Pregnancy Category X), but the supplied excerpt uses “is contraindicated” wording. “Should not be used” is not directly quoted; while conceptually consistent, it is not explicitly stated in the provided excerpt as such.
Contradictions
Low
AI Statement
Lipitor (atorvastatin) is contraindicated during breastfeeding.
Label Reference
No breastfeeding contraindication text was provided; therefore this statement cannot be confirmed. It is treated as unsupported rather than contradicted because the label excerpt set does not affirm an opposite position.
Important Omissions
For the liver abnormality claim, the label excerpt specifies timing and thresholds (e.g., LFTs prior to and at 12 weeks; persistent ALT/AST >3x ULN, then dose reduction or withdrawal). The AI claim does not include the threshold/timing details, which are material for accurate label-concordant management.
Importance:
Moderate
For the pregnancy claims, the label excerpt also specifies that “LIPITOR may cause fetal harm when administered to a pregnant woman” and that the patient should be apprised of potential hazard; the AI claims do not reflect this counseling element.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple pregnancy-related elements are directionally consistent, but unsupported contraindications (especially breastfeeding) and partially supported liver contraindications create risk of inaccurate safety guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Several claims are unsupported by the provided FDA label excerpts (notably hypersensitivity and breastfeeding contraindication), and liver contraindication support is incomplete/indirect because the Contraindications section excerpt shown only includes pregnancy.
Suggested Improvement
Limit contraindication statements to those explicitly supported by the provided label excerpts (Pregnancy is supported). For liver dysfunction, cite the label excerpt wording and include that it is based on “active liver disease or unexplained persistent transaminase elevations,” while ensuring the contraindication section text is actually provided. Remove or qualify hypersensitivity and breastfeeding contraindication claims unless breastfeeding-specific label text is supplied.